scholarly journals Connecting the Missing Link Between Dilated Cardiomyopathy and Viral Myocarditis

Circulation ◽  
2007 ◽  
Vol 115 (1) ◽  
pp. 5-8 ◽  
Author(s):  
Yuichiro Maekawa ◽  
Maral Ouzounian ◽  
M. Anne Opavsky ◽  
Peter P. Liu
Keyword(s):  
Dilated Cardiomyopathy ◽  
Viral Myocarditis ◽  
Missing Link

scholarly journals The Protective Effects of Ivabradine in Preventing Progression from Viral Myocarditis to Dilated Cardiomyopathy

2016 ◽  
Vol 7 ◽  
Author(s):  
Li Yue-Chun ◽  
Chen Guang-Yi ◽  
Ge Li-Sha ◽  
Xing Chao ◽  
Tian Xinqiao ◽  
...  
Keyword(s):  
Dilated Cardiomyopathy ◽  
Viral Myocarditis ◽  
Protective Effects

scholarly journals An Echocardiographic Presentation of Severe Dilated Cardiomyopathy Due to Acute Viral Myocarditis From Coxsackie B Enterovirus

2018 ◽  
Vol 34 (3) ◽  
pp. 230-236
Author(s):  
Alison White
Keyword(s):  
Dilated Cardiomyopathy ◽  
Systolic Function ◽  
Acute Myocarditis ◽  
Diagnostic Testing ◽  
Viral Myocarditis ◽  
Infectious Agent ◽  
Case Presentation ◽  
Testing Method ◽  
Function Impairment ◽  
Coxsackie B

Dilated cardiomyopathy (DCM) is a disease of the myocardium characterized by changes in cardiac chamber dimension and initial deterioration in systolic function accompanied by eventual diastolic function impairment with possible progression to cardiac failure. Early identification of ventricular dysfunction and etiology is imperative for the subsequent effective treatment of the cardiomyopathy process. One common cause of DCM is an infection from a viral insult that results in inflammation and consequent damage to the myocardium. Viral myocarditis may present as an acute or chronic illness. The clinical presentation of myocarditis demonstrates nonspecific symptomology that is variable between individuals. Accurate diagnosis of viral myocarditis relies upon various diagnostic testing methods to ascertain the origin of the infectious agent and resultant alterations in cardiovascular function. One such diagnostic testing method used in the detection of the presence and severity of DCM associated with viral myocarditis is echocardiography. The following case presentation demonstrates a dilated cardiomyopathy due to an acute myocarditis from Coxsackie B enterovirus evaluated with echocardiography.

Death of a 3 Month-Old Infected Infant with Dilated Cardiomyopathy after COVID-19 Infection: A Case Report

2021 ◽  
Author(s):  
Fatemeh Baghalsafa ◽  
Hossein Neamatzadeh ◽  
Sedigheh Ekraminasab
Keyword(s):  
Case Report ◽  
Dilated Cardiomyopathy ◽  
Cardiac Injury ◽  
Viral Myocarditis ◽  
Rare Condition ◽  
Underlying Disease ◽  
Pediatric Emergency ◽  
Sufficient Evidence ◽  
Infected Infant ◽  
Severe Underlying Disease

Background: Several numbers of studies have reported that coronavirus disease-2019 (COVID-19) in infants and children have shown milder symptoms and a better prognosis than in adult patients. However, there is no sufficient evidence on the effect of cardiovascular involvement in COVID-19 in the infant. Case Report: Here, we report an infant infected with COVID-19 with the manifestations of dilated myocarditis. The patient was referred to Pediatric Emergency with lethargy and tachypnea. On physical examination, she had holosystolic murmur with grade 3/6. The laboratory examinations showed anemia as well as increased alkaline phosphatase (ALP) levels. Due to respiratory distress, she was intubated and put under mechanical ventilation. The diagnosis of COVID-19 infection was confirmed by real-time polymerase chain reaction (RT-PCR) using a pharyngeal specimen. Finally, dilated cardiomyopathy (DCM) was diagnosed and one day after hospitalization the infant was died due to complications of DCM. Conclusion: It seems that in the infant with severe underlying disease, even a mild COVID-19 infection, may be lethal. Focal viral myocarditis is a very rare condition described by localized disturbance of the myocardium occurring in ventricular dysfunction with significant morbidity and mortality. Thus, due to the possibility of cardiac injury in infected neonates with COVID-19 disease and the manifestation of myocarditis, effective measurement is recommended.

Paediatric dilated cardiomyopathy: clinical profile and outcome. The experience of a tertiary centre for paediatric cardiology

2014 ◽  
Vol 25 (2) ◽  
pp. 333-337 ◽  
Author(s):  
Joana O. Miranda ◽  
Liane Costa ◽  
Esmeralda Rodrigues ◽  
Elisa L. Teles ◽  
Maria J. Baptista ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Dilated Cardiomyopathy ◽  
Metabolic Diseases ◽  
Parvovirus B19 ◽  
Viral Myocarditis ◽  
Paediatric Population ◽  
Clinical Profile ◽  
Age At Diagnosis ◽  
Inherited Metabolic Diseases ◽  
Tertiary Centre

AbstractDilated cardiomyopathy is the most common form of cardiomyopathy in the paediatric population and an important cause of heart transplantation in children. The clinical profile and course of dilated cardiomyopathy in children have been poorly characterised. A retrospective review of 61 patients (37 female; 24 male) diagnosed with dilated cardiomyopathy from January, 2005 to June, 2012 at a single institution was performed. The median age at diagnosis was 15 months. Heart failure was present in 83.6% of patients and 44.3% required intensive care. The most prevalent causes were idiopathic (47.5%), viral myocarditis (18.0%) and inherited metabolic diseases (11.5%). In viral myocarditis, Parvovirus B19 was the most common identified agent, in concurrence with the increasing incidence documented recently. Inherited metabolic diseases were responsible for 11.5% of dilated cardiomyopathy cases compared with the 4–6% described in the literature, which reinforces the importance of considering this aetiology in differential diagnosis of paediatric dilated cardiomyopathy. The overall mortality rate was 16.1% and five patients underwent heart transplantation. In our series, age at diagnosis and aetiology were the most important prognosis factors. We report no mortality in the five patients who underwent heart transplantation, after 2 years of follow-up.

scholarly journals Roles of Host Immunity in Viral Myocarditis and Dilated Cardiomyopathy

2018 ◽  
Vol 2018 ◽  
pp. 1-12 ◽  
Author(s):  
Lifang Zhao ◽  
Zhaoying Fu
Keyword(s):  
Innate Immunity ◽  
T Cell ◽  
Immune Responses ◽  
Viral Infection ◽  
Dilated Cardiomyopathy ◽  
Viral Myocarditis ◽  
Host Immunity ◽  
Host Immune Responses ◽  
Direct Damage ◽  
Working Together

The pathogenesis of viral myocarditis includes both the direct damage mediated by viral infection and the indirect lesion resulted from host immune responses. Myocarditis can progress into dilated cardiomyopathy that is also associated with immunopathogenesis. T cell-mediated autoimmunity, antibody-mediated autoimmunity (autoantibodies), and innate immunity, working together, contribute to the development of myocarditis and dilated cardiomyopathy.

scholarly journals OPTIMIZATION OF ACUTE MYOCARDITIS TREATMENT

2019 ◽  
Vol 26 (2) ◽  
pp. 224-229
Author(s):  
Svetlana A. Chepurnenko ◽  
Galina V. Shavkuta ◽  
Alina D. Nasytko
Keyword(s):  
Dilated Cardiomyopathy ◽  
Normal Values ◽  
Enzyme Inhibitor ◽  
Acute Myocarditis ◽  
Viral Myocarditis ◽  
Cumulative Effect ◽  
Reverse Remodeling ◽  
Mineralocorticoid Receptor Antagonist ◽  
Acute Viral Myocarditis ◽  
Heart Size

Aim. This paper is aimed at investigating the possibility of preventing an adverse outcome of acute viral myocarditis by means of optimal pharmacotherapy without the use of surgical treatment methods.Results. We describe a clinical case of acute viral myocarditis in a 60-year old female patient. According to the conducted echocardioscopy, the dilatation of the heart cavities and the complete insufficiency of the mitral and tricuspid valves were identified. A cumulative effect of the chosen optimal pharmacotherapy, which included an angiotensin converting enzyme inhibitor, a beta-blocker, a mineralocorticoid receptor antagonist and a loopback diuretic with neurohumoral properties taken in optimal doses, allowed congestion signs to be rapidly eliminated, a reverse remodeling of the heart to be achieved and the heart size to be returned normal values. The double blockade of aldosterone receptors using eplerenone and torasemide prevented both the development of fibrosis in the myocardium and the formation of irreversible dilated cardiomyopathy.Conclusion. The application of antiviral and immunomodulatory therapy, along with the maximum possible doses of drugs used to treat chronic heart failure, allowed the patient’s cardiohemodynamic parameters to be returned to normal values. A timely combination therapy should be used to avoid the formation of dilated cardiomyopathy, thus improving the prognosis of the disease. 

Sign in / Sign up

Export Citation Format

Share Document